Exciting Stem Cell (FDA:HCT/P) News
Placental/Umbilical Tissues/Biological Allografts (FDA: HCT/P – Stem Cells)
We are excited to inform you that under the guidance of the Food and Drug Administration, with the legal and regulatory expertise of Hyman, Phelps & McNamara, and with the cellular, biological and tissue laboratory expertise of Vitti Labs, our Regenerative Medicine program, which utilizes biological allografts (i.e., stem cells), including cells derived from umbilical and placental tissues, is currently in the process of being restructured.
Indeed, AMA and Vitti are partnering to pursue a number of Investigational New Drug (IND) studies in order to administer stem cells for the treatment of various conditions such as Duchenne Muscular Dystrophy, Autism, and Idiopathic Pediatric Autoimmune Disorders.
Please check back with us for updates and information regarding these studies.